Decline in esophageal candidiasis and use of antimycotics in European patients with HIV

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1446-1454

  Mocroft, Amanda ^a   Oancea, Cristina ^b   Van Lunzen, Jan ^c   Vanhems, Philippe ^d   Banhegyi, Denes ^e   Chiesi, Antonio ^f   Vinogradova, Elena ^g   Maayan, Shlomo ^h   Phillips, Andrew N ^a   Lundgren, Jens ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Eppendorf Medizinische Kernklinik   (Germany)

^d UNIVERSITÉ LYON 1   (France)

^e Szent Laszlo Hospital   (Hungary)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g St Petersburg Munic Geriatric Ctr   (Russian Federation)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CANDIDIASIS; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; VIRUS LOAD;

EID: 22744432652     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41949.x     Document Type: Article

References (33)

1. Vazquez JA. Invasive oesophageal candidiasis: Current and developing treatment options (Review). Drugs 2003;63:971-89.
2. Moore RD, Chaisson RE. Natural history of opportunistic diseases in an HIV-1 infected urban clinical cohort. Ann Intern Med 1996;124:633-42.
3. Lundgren JD, Pederson C, Clumeck N, et al. Survival differences in patients with AIDS, 1979-1989. BMJ 1994;308:1068-73.
4. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: A propspective observational study of 2625 patients. BMJ 1997;314:409-13.
5. Crowe SM, Carlin JB, Steward KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
6. Luo K, Law M, Kaldor JM, et al. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995;9:57-63.
7. Mocroft AJ, Lundgren JD, d'Arminio Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol 1997;26:400-7.
8. Wilcox CM, Darouichie RO, Laine L, et al. A randomised, double-blinded comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176:227-32.
9. Barbara G, Barbarino G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996;111:1169-77.
10. De Wit S, Weerts D, Goessens H, et al. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;333:746-7.
11. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991; 151:2458-64.
12. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV - November 28, 2001. http://AIDSinfo.nih.gov/ guidelines (accessed 11 August 2004).
13. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe; 1994-1998: The EuroSIDA study. Lancet 2000;356:291-6.
14. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
15. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:S5-14.
16. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15:347-55.
17. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-9.
18. Cauda R, Tacconelli E, Tumbarelli M, et al. Role of protease inhibitors in preventing oral candidiasis on patients with HIV infection: A prospective case-control study. J Acquir Immune Defic Syndr 1999;21:20-5.
19. Hood S, Bonington A, Evans J, et al. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998;12:447-8.
20. Nicolatou-Galitis O, Velegraki A, Paikos S, et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004; 10:145-50.
21. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses after initiation of potent antiretroviral therapy. JAMA 1999;282:2220-6.
22. Mocroft A, Sabin CA, Youle M, et al. Changes in AIDS defining illnesses in a London clinic, 1987-1998. J Acquir Immune Defic Syndr 1999;21:401-7.
23. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001;42:134-9.
24. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8.
25. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-42.
26. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of CNS HIV-related diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320-8.
27. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi's sarcoma in patients with HIV-1994-2003. The EuroSIDA study. Cancer 2004;100:2644-54.
28. Mitchelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815-22.
29. Law MG, de Winter L, McDonald A, et al. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral therapy. AIDS 1999;13:263-9.
30. Powderly WG, Gallant JG, Ghannoum MA, et al. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy. AIDS Res and Hum Retroviruses 1999;15:1619-23.
31. Carpenter CCJ, Fischl MA, Hammer SN, et al. Antiretroviral therapy for HIV in 1996: Recommendations of an international panel. JAMA 1996;276:146-54.
32. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection-2004 recommendations of the international AIDS society-USA panel. JAMA 2004;292:251-65.
33. Cassone A, De Bernadis F, Torosantrucci A, et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-53.